[Articles] Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial

Journal content Created on 25 Aug 2026 The Lancet Oncology

• Details
• • All feed content
  • My feed content